Scancell Holdings plc (AIM:SCLP)
13.50
+1.00 (8.00%)
Apr 15, 2026, 5:08 PM GMT
Scancell Holdings Employees
Scancell Holdings had 60 employees as of April 30, 2025. The number of employees decreased by 1 or -1.64% compared to the previous year.
Employees
60
Change (1Y)
-1
Growth (1Y)
-1.64%
Revenue / Employee
78.52K GBP
Profits / Employee
-91.85K GBP
Market Cap
140.10M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Apr 30, 2025 | 60 | -1 | -1.64% |
| Apr 30, 2024 | 61 | 10 | 19.61% |
| Apr 30, 2023 | 51 | 11 | 27.50% |
| Apr 30, 2022 | 40 | 15 | 60.00% |
| Apr 30, 2021 | 25 | 3 | 13.64% |
| Apr 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Oxford Biomedica | 977 |
| hVIVO | 301 |
| Avacta Group | 151 |
| 4basebio | 110 |
| PureTech Health | 56 |
| Faron Pharmaceuticals Oy | 33 |
| Hemogenyx Pharmaceuticals | 16 |
| Poolbeg Pharma | 16 |
Scancell Holdings News
- 2 months ago - Scancell announces FDA clearance of IND application for global Phase 3 trial of iSCIB1+ in advanced melanoma - GlobeNewsWire
- 7 months ago - Scancell reports Business Update and Financial Results for the Year Ended 30 April 2025 - GlobeNewsWire
- 9 months ago - Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+ - GlobeNewsWire
- 1 year ago - PharmaJet and Scancell Sign Strategic Partnership Agreement for Development and Commercialization of a Needle-free DNA Vaccine for Advanced Melanoma - Business Wire
- 2 years ago - PharmaJet Partner, Scancell, Announces Positive Data from the First Stage of its Phase 2 Trial of Advanced Melanoma DNA Vaccine delivered Needle-free - Business Wire